Table 1.
Patient baseline characteristics.
| All Patients (n = 79) |
Patients with ATTR (n = 65) |
Patients with AL (n = 14) |
|
|---|---|---|---|
| N (% of total cohort) | 79 (100) | 65 (82.3) | 14 (17.7) |
| Age (years), median (quartiles) | 80 | 80 (75; 84) | 64 (59; 68) |
| Female sex, n (%) | 22 (21.5) | 13 (32.9) | 9 (35.7) |
| NYHA functional class, median (range) | 3 (1–3) | 3 (1–3) | 2 (1–3) |
| HFrEF/HFmrEF/HFpEF, n (%) | 12 (63)/17 (22)/50 (15) | 12 (18)/14 (22)/39 (60) | 0 (0)/3 (21)/11 (79) |
| NT-proBNP (pg/mL), median (quartiles) | 2213 (948; 3611) | 2159 (1062; 3636) | 2387 (617; 3172) |
| hs-TropT (pg/mL), median (quartiles) | 41.3 (29.3; 72.3) | 43.9 (29.8; 72.4) | 34.3 (13.5; 59.1) |
| CKD G1/2/3a/3b/4, n (%) | 2 (2.5)/22 (27.8)/16 (20.3)/27 (34.2)/11 (13.9) | 1 (1.5)/20 (30.8)/11 (16.9)/24 (36.9)/9 (13.8) | 1 (7.1)/2 (14.3)/5 (35.7)/4 (28.6)/2 (14.3) |
| Diabetes, n (%) | 17 (21.5) | 12 (18.5) | 5 (35.7) |
| Known coronary heart disease, n (%) | 23 (29.1) | 22 (33.8) | 1 (7.1) |
| Hypertension, n (%) | 50 (63.3) | 42 (64.6) | 8 (57.1) |
| Atrial fibrillation, n (%) | 41 (51.9) | 40 (61.5) | 1 (7.1) |
| Pacemaker, n (%) | 12 (15.2) | 11 (16.9) | 1 (7.1) |
| ICD, n (%) | 2 (2.5) | 2 (2.5) | 0 (0) |
| CRT, n (%) | 2 (2.5) | 2 (2.5) | 0 (0) |
CKD G: Chronic Kidney Disease Grade (KDIGO staging); CRT: cardiac resynchronization therapy, biventricular pacemaker. HFrEF: heart failure with reduced ejection fraction. HFmrEF: heart failure with mid-range ejection fraction. HFpEF: heart failure with preserved ejection fraction. Hs-TropT: highly sensitive troponin T. ICD: implantable cardioverter defibrillator. NT-proBNP: N-terminal pro-hormone brain-natriuretic peptide. NYHA: New York Heart Association.